Focused On-demand Library for SLIT and NTRK-like protein 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9H5Y7

UPID:

SLIK6_HUMAN

Alternative names:

Alternative UPACC:

Q9H5Y7; A8K9S8; Q495Q0; Q6AW93; Q9HAA8; Q9NT60

Background:

SLIT and NTRK-like protein 6 plays a pivotal role in the regulation of neurite outgrowth, which is essential for the development of the nervous system. This protein's functionality is crucial for maintaining normal hearing and vision, highlighting its significance in sensory perception.

Therapeutic significance:

Given its involvement in deafness and myopia, a rare autosomal recessive disorder, SLIT and NTRK-like protein 6 presents a promising target for therapeutic intervention. Understanding the role of SLIT and NTRK-like protein 6 could open doors to potential therapeutic strategies aimed at mitigating the symptoms or possibly correcting the underlying genetic causes of these conditions.